Another senior AstraZeneca exec jumps ship; Aldeyra shares soar on positive mid-stage data

⇨ Another senior AstraZeneca R&D exec has jumped ship. Sanjay Jariwala is moving on to Biogen, where he will be the new senior vice president, worldwide medical, reporting to Al Sandrock. “Sanjay’s depth of experience and track record of strategic integration of global therapeutic operations, clinical development, commercial, and state of the art medical leadership across large organizations is impressive,” said Sandrock.

⇨ Shares of Aldeyra Therapeutics $ALDX spiked 53% Tuesday morning after the biotech reported positive Phase IIa data on its topical ocular ADX-102 in patients with dry eye disease. “These data represent the fourth set of positive Phase II results with ADX-102 in ocular inflammation. The breadth of activity across noninfectious anterior uveitis, allergic conjunctivitis, and now dry eye disease confirms the potential of ADX-102 as an important and differentiated therapy in ophthalmology,” commented Todd Brady, CEO of Aldeyra.

Deciphera has taken another step toward launching its IPO, with $100 million pencilled in as the target. The biotech will trade as {$DCPH.}

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,400+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->